Elevated Levels of Plasma Transforming Growth Factor‐β in Patients with Hepatocellular Carcinoma

Open Access
Publisher Website
Google Scholar
Abstract
We measured the plasma transforming growth factor‐β (TGF‐β) concentration in 14 patients with human hepatocellular carcinoma (HCC) and 9 age‐matched normal subjects using growth inhibition assay of mink lung epithelial cells. The calculated plasma TGF‐β concentration in the patients with HCC was 28.6 ± 27.9 ng/ml (mean± SE), showing significant elevation compared with that in 9 normal subjects (5.3 ± 3.3 ng/ml, P<0.01). In three cases, we could measure plasma TGF‐β levels before and after their treatment for HCC. The plasma TGF‐β levels decreased from 59.0 to 18.2 ng/ml after hepatic resection in one case, and from 24.0 to 10.7 ng/ml and from 12.4 to 3.4 ng/ml after transhepatic arterial embolization in the other two cases. These data indicate that plasma TGF‐β level is elevated in patients with HCC, probably due to release from HCC tissues.